Chordia Therapeutics Inc.
Research Chordia Therapeutics Inc. (190A.T) on Bullrun: market cap JPY 4.21B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker190A.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 4.21B
- Financial periodFY2025
- RevenueJPY 0
- Net income-JPY 1.79B
- Free cash flow-JPY 1.84B
Valuation Snapshot
latest market cap is JPY 4.21B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 0 | -JPY 1.79B | -JPY 1.84B | n/a | -26.03 | JPY 2.55B | n/a | JPY 2.44B |
| FY2024 | JPY 0 | -JPY 1.83B | -JPY 1.94B | n/a | -31.11 | JPY 4.33B | n/a | JPY 4.16B |
| FY2023 | JPY 2.50B | JPY 223.34M | JPY 543.01M | 20.1% | 3.96 | JPY 4.80B | n/a | JPY 4.50B |
| FY2022 | JPY 0 | -JPY 1.78B | -JPY 1.72B | n/a | -31.52 | JPY 4.25B | n/a | JPY 4.28B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 4.21B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About Chordia Therapeutics Inc.
Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Chordia Therapeutics Inc.'s market cap?
Chordia Therapeutics Inc.'s market capitalization is JPY 4.21B.
What does Chordia Therapeutics Inc. do?
Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan.